Human SR-AI/MSR Alexa Fluor® 405-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB2708V
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Lys77-Leu451
Accession # P21757
Specificity
Clonality
Host
Isotype
Applications for Human SR-AI/MSR Alexa Fluor® 405-conjugated Antibody
Flow Cytometry
Sample: THP-1 human acute monocytic leukemia cell line treated with PMA and Ca2+ ionomycin
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
Background: SR-AI/MSR
The type I class A macrophage scavenger receptor (SR-AI; also MSR-AI) is a 70-80 kDa protein that belongs to the scavenger receptor superfamily (1‑3). Receptors of this family contain characteristic extracellular domains and bind to a series of generally unrelated, but negatively-charged/polyanionic ligands (1, 3). Human SR-AI is a type II transmembrane glycoprotein that is 451 amino acids (aa) in length. It contains a 50 aa cytoplasmic tail, a 26 aa transmembrane segment and a 375 aa extracellular region (4, 5). The extracellular region contains four definitive domains, with a membrane proximal spacer of 33 aa, an alpha-helical coiled-coil domain of 163 aa, a collagen-like domain of 69 aa, and a cysteine-rich C-terminus of 110 aa (4, 6). The cysteine-rich domain (CRD) forms three intrachain disulfide bonds (7). The functional form of the molecule is a 220‑230 kDa membrane-associated trimer that, in human, apparently has two disulfide bonded chains and a third noncovalently associated subunit (8, 9). Human extracellular region is 73% and 72% aa identical to bovine and mouse SR-AI extracellular region, respectively. The human gene for SR-A gives rise to three isoforms; the I isoform of 451 aa, the II isoform of 358 aa, and the III isoform of 388 aa (4, 5, 10). All are identical through the first 344 aa which includes the cytoplasmic tail through the collagenous domain. Isoform II (SR-AII) shows a severe truncation of the CRD, but is expressed on the cell surface. Isoform III (SR-AIII) has a modest truncation of the CRD, and cannot be expressed on the cell surface. However, relative to SR-AI, SR-AII is known to show differential sensitivity to LPS and receptor binding to gram‑negative bacteria (9, 11), while SR-AIII is known to be a dominant-negative isoform (10). SR-AIII may achieve this by either heterotrimerizing with SR-AI, or simply eliminating the production of SR-AI mRNA.
References
- Platt, N. and S. Gordon (2001) J. Clin. Invest. 108:649.
- Linton, M.F. and S. Fazio (2001) Curr. Opin. Lipidol. 12:489.
- Platt, N. and S. Gordon (1998) Chem. Biol. 5:R193.
- Matsumoto, A. et al. (1990) Proc. Natl. Acad. Sci. USA 87:9133.
- Emi, M. et al. (1993) J. Biol. Chem. 268:2120.
- Naito, M. et al. (1992) Am. J. Pathol. 141:591.
- Resnick, D. et al. (1996) J. Biol. Chem. 271:26924.
- Ashkenas, J. et al. (1993) J. Lipid Res. 34:983.
- Penman, M. et al. (1991) J. Biol. Chem. 266:23985.
- Gough, P.J. et al. (1998) J. Lipid Res. 39:531.
- Peiser, L. et al. (2000) Inf. Immun. 68:1953.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional SR-AI/MSR Products
Product Documents for Human SR-AI/MSR Alexa Fluor® 405-conjugated Antibody
Product Specific Notices for Human SR-AI/MSR Alexa Fluor® 405-conjugated Antibody
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only